Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input

This article was originally published in The Tan Sheet

Executive Summary

FDA will consider "public comment of the widest kind" from the "layperson to health professionals to scientists" in analyzing and changing portions of the June 1997 proposed rule on ephedrine alkaloids in dietary supplements, Commissioner Jane Henney, MD, testified at a congressional hearing Feb. 29.

Related Content

Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin
Ephedra/AER Causality Link Not Possible - Cantox/CRN
GAO and nutritionals
Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA
Ephedrine alkaloids
Dietary Supplement Enforcement Procedure Streamlining Planned By CFSAN
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA Ephedrine Adverse Event Data Questioned By GAO
Ephedrine Alkaloid AERs Down, Ratio Of Serious Events Up - FDA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts